2016 Biomax Symposium: Bringing big and complex data into clinical practice

24 June 2016, Martinsried, Germany.
Biomax announces the 2016 Biomax Symposium on "Bringing Big and Complex Data into Clinical Practice" that will take place in Martinsried (near Munich), Germany. This year's Biomax Symposium focuses on how clinical practice and patient treatment can benefit from big and complex data. It will cover the challenges and requirements that need to be addressed in a clinical setting: from gathering big data, guaranteeing data security in daily practice and fostering feedback between complex clinical data and research, to learning from the data to make better treatment decisions. In a nutshell, the symposium will cover using big and complex data to treat the individual with the knowledge of all.

Biomax has hosted this biennial event since 2012 to facilitate the discussion between clinical management and practitioners, pharma, "Big Data" researchers, health insurance payers, public health and government representatives, funding providers, as well as patient representatives. Through the symposium Biomax hopes to share their own and other experiences in implementing such programs. Past symposia have been a popular forum for these important players to learn from each other and discuss the way forward.

Invited speakers and panel discussion participants are leaders from clinical research, healthcare organizations, international research projects and government. The opening session includes presentations by:

  • Prof. Dr. Emiel Wouters, Department of Respiratory Medicine, University Medical Centre, Maastricht
  • Henning Schneider, CIO at the University Medical Center Hamburg-Eppendorf
  • Prof. Dr. Hans-Werner Mewes, School of Life Sciences, Technische Universität München

The symposium is free of charge.

For further information and to register, please visit:
http://www.biomax.com/symposiums/biomax-symposium-2016/

About Biomax
Biomax Informatics AG is a leader in the development of computational solutions for the life sciences. Biomax provides the BioXM™ Knowledge Management Environment and other computational solutions, including the Viscovery® data-mining technology, for better decision making and knowledge management in biomarker identification, patient stratification and targeted medicine. They help customers generate value by integrating information from proprietary and public resources to enable a knowledge-based approach to developing innovative life science products. Biomax’s worldwide customer community includes medical clinics, research organizations and companies that are successful in drug discovery, diagnostics, fine chemicals, food and plant production and healthcare.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...